RYZNEUTA Solution for injection Ref.[110038] Active ingredients: Efbemalenograstim alfa

Source: European Medicines Agency (EU)  Revision Year: 2024  Publisher: Evive Biotechnology Ireland LTD, 20 Kildare Street, Dublin 2, D02 T3V7, Ireland

Product name and form

Ryzneuta 20 mg solution for injection.

Pharmaceutical Form

Solution for injection (injection).

Clear, colourless solution for injection.

Qualitative and quantitative composition

Each pre-filled syringe contains 20 mg of efbemalenograstim alfa* in 1 mL solution for injection. The concentration is 20 mg/mL.

* Recombinant human granulocyte colony-stimulating factor Fc fusion protein derived from mammalian cell culture.

The potency of this medicinal product should not be compared to the potency of another protein (pegylated or non-pegylated) of the same therapeutic class. For more information, see section 5.1.

Excipient with known effect: Each prefilled syringe contains 50 mg sorbitol (E420).

For the full list of excipients, see section 6.

Active Ingredient Description
Efbemalenograstim alfa

Human granulocyte-colony stimulating factor (G-CSF) is a glycoprotein, which regulates the production and release of neutrophils from the bone marrow. Efbemalenograstim alfa is a recombinant fusion protein containing G-CSF, a 16 amino-acid linker, and the Fc portion of human IgG2. Efbemalenograstim alfa is a sustained duration form of G-CSF due to decreased renal clearance. Efbemalenograstim alfa and other G-CSFs have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.

List of Excipients

Sodium acetate trihydrate
Glacial acetic acid
Sorbitol (E420)
Polysorbate 20
Edetic acid
Water for injections

Pack sizes and marketing

Pre-filled syringe (Type I glass), with a rubber stopper, stainless steel needle and needle cap.

The needle cap on the prefilled syringe contains dry natural rubber (latex) (see section 4.4).

Each pre-filled syringe contains 1 mL of solution for injection.

Pack size of one pre-filled syringe

Marketing authorization holder

Evive Biotechnology Ireland LTD, 20 Kildare Street, Dublin 2, D02 T3V7, Ireland

Marketing authorization dates and numbers

EU/1/24/1793/001

Date of first authorisation: 21 March 2024

Drugs

Drug Countries
RYZNEUTA Lithuania, United States

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.